New Pediatric Indication for Cefazolin for Injection USP in Duplex
BETHLEHEM, PA – December 9, 2020 – B. Braun Medical Inc. announced that they have received FDA approval for use of Cefazolin for Injection and Dextrose Injection 1gm and 2gm in Duplex in pediatric patients. A post market requirement (PMR) safety study was conducted in pediatric patients. This drug is now approved for treatment of infections in pediatric patients and for perioperative prophylaxis in patients age 10 to 17.
Please see full Prescribing Information at https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17f8f038-c204-4dab-80d7-6f7ac41ddbec.
The DUPLEX® Drug Delivery System is a ready-to-use dual-Chamber IV bag designed to simplify intravenous antibiotic delivery to patients, minimize the potential for medication errors, and help eliminate the pharmacy labor component of IV antibiotic delivery and reduce drug waste.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. Other key product areas include nutrition, pharmacy admixture and dialysis. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, PA and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website.